Literature DB >> 2585274

Simultaneous determination of propranolol enantiomers in plasma by high-performance liquid chromatography with fluorescence detection.

C Prakash1, R P Koshakji, A J Wood, I A Blair.   

Abstract

A simple, rapid, and sensitive assay for the simultaneous quantification of the (-)- and (+)-propranolol in human and dog plasma is described using a reversed-phase high-performance liquid chromatography (HPLC) system with fluorescence detection. The method involves extraction of propranolol enantiomers from plasma into 1% 1-butanol in n-hexane at basic pH, followed by evaporation of the organic phase and the formation of diastereomeric derivatives with the chiral reagent (-)-menthyl chloroformate. (+)-Flecainide is used as the internal standard. The limiting concentration of each enantiomer that can be detected is 1 ng/mL plasma. In six normal human volunteers, who received a single oral dose of 80 mg of racemic propranolol, the plasma levels of the (-)-enantiomer were always higher than those of the (+)-enantiomer with a mean (-):(+) ratio of 1.38. The half-lives of both the enantiomers were similar (3.5 +/- 0.3 h). In six normal male mongrel dogs given a single intraportal dose of 40 mg of racemic propranolol, the plasma levels of the (-)-enantiomer were always lower than those of the (+)-enantiomer with a mean (-):(+) ratio of 0.48. The half-life of the (-)-enantiomer (73.3 +/- 16.2 min) was shorter than that of the (+)-enantiomer (87.1 +/- 18.1 min).

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2585274     DOI: 10.1002/jps.2600780915

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  3 in total

1.  Lack of effect of ageing on the stereochemical disposition of propranolol.

Authors:  H H Zhou; E Whelan; A J Wood
Journal:  Br J Clin Pharmacol       Date:  1992-01       Impact factor: 4.335

2.  Iontophoretic in vivo transdermal delivery of beta-blockers in hairless rats and reduced skin irritation by liposomal formulation.

Authors:  Rajkumar Conjeevaram; Ayyappa Chaturvedula; Guru V Betageri; Gangadhar Sunkara; Ajay K Banga
Journal:  Pharm Res       Date:  2003-09       Impact factor: 4.200

3.  Erythrocyte G protein as a novel target for malarial chemotherapy.

Authors:  Sean C Murphy; Travis Harrison; Heidi E Hamm; Jon W Lomasney; Narla Mohandas; Kasturi Haldar
Journal:  PLoS Med       Date:  2006-12       Impact factor: 11.069

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.